Regeneron & BARDA collaborate for MERS treatment: 3 points

Tarrytown, N.Y.-based Regeneron Pharmaceuticals is teaming up with the Biomedical Advanced Research and Development Authority and HHS to create a Middle East Respiratory Syndrome treatment, according to FierceBiotech.

Here are three points:

1. The groups will develop a pair of antibodies to prevent and treat MERS.

2. HHS will allot $8.9 million to Regeneron for manufacturing, the investigational new drug application and an National Institutes of Health clinical trial.

3. Currently, no drugs exist to treat or prevent MERS.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers

Featured Podcast